Attached files

file filename
EX-99 - PRESS RELEASE, DATED FEBRUARY 11, 2015 - NeuBase Therapeutics, Inc.ex99-1.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 


Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 11, 2015

 

Ohr Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)

         
Delaware   333-88480   #46-5622433
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)

 

     
800 Third Avenue, 11th Floor, New York, NY   10022
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (212)-682-8452

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 7.01 Regulation FD Disclosure

Public Offering Announcement

On February 11, 2015, the registrant issued a press release announcing that it completed an underwritten public offering of 4,259,259 of its common shares, including 555,555 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $6.75 per share, and the gross proceeds to the Company from the sale of the shares were approximately $28.8 million.

A copy of the above referenced press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. This information, including the information contained in the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company’s filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

 

 

Exhibit No.   Description
99.1   Press Release, dated February 11, 2015
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OHR PHARMACEUTICAL, INC.  
       
  By: /s/ Irach Taraporewala  
    Dr. Irach Taraporewala, President and CEO  
  Dated: February 11, 2015